Efficacy and safety of Ban-Lan-Gen granules in the treatment of seasonal influenza: study protocol for a randomized controlled trial

Zheng-tu Li, Li Li, Ting-ting Chen, Chu-yuan Li, De-qin Wang, Zi-feng Yang, Nan-shan Zhong, Zheng-tu Li, Li Li, Ting-ting Chen, Chu-yuan Li, De-qin Wang, Zi-feng Yang, Nan-shan Zhong

Abstract

Background: Ban-Lan-Gen (BLG) is a traditional Chinese herbal medicine. It has been used for the prevention and treatment of virus-related respiratory diseases such as influenza virus infection. BLG contains some antiviral compounds, but few evidence-based clinical studies have been conducted to assess its efficacy against influenza. We assessed the effects of BLG (including efficacy and safety) on the treatment of seasonal influenza in an evidence-based clinical trial.

Methods/design: We conducted a randomized, double-blinded, oseltamivir- and placebo-controlled, parallel-design clinical trial. A total of 177 subjects are going to be recruited after satisfying the criteria: (i) 18 to 65 years of age; (ii) illness onset within 36 h; (3) axillary temperature ≥38.0°C; and (iv) positive influenza (type A/B) virus test. Subjects will be assigned randomly into three groups in equal proportions: oseltamivir treatment, BLG granule treatment, and placebo treatment. Each group receives 5-day treatment and is followed up 1, 3, 5, 7 and 21 days later. Symptoms and patient compliance are recorded, and virus/serum viral antibodies tested. We will use the primary outcome, secondary outcome, and safety indicators to evaluate the efficacy and safety of BLG granules in the treatment of seasonal influenza.

Discussion: We have described the first clinical trial for treatment using a single herb against influenza A and B viruses in China. We will hold a large-scale clinical trial to comprehensively evaluate the effectiveness and safety of BLG against influenza infection based on the results of this pilot study. And this clinical trial will serve as an example for the study of other traditional herbal medicines in evidence-based clinical trials.

Trial registration: This study has been registered at ClinicalTrials.gov: NCT02232945 (3 September 2014).

Figures

Figure 1
Figure 1
Study flowchart. Participants with a rapid diagnosis of influenza will be recruited, and they will be assigned randomly into three different groups. All participants will accept the 5-day treatment and 21-day follow-up period observation. The data were collected to determine the treatment efficacy and safety of Ban-Lan-Gen (BLG).

References

    1. Fengxing Y, Liwen J, Zhang J, Shi Q, Ma G, Ji X, et al. Research on the specificity and sensitivity of rapid detection methods of influenza virus. Lab Med. 2009;24:598–04.
    1. Zhong Nanshan LY. Respiratory Medicine. People’s Medical Publishing House. 2012;2:387–93.
    1. Centers for Disease Control and Prevention (CDC) Swine-origin influenza A (H1N1) virus infections in a school - New York City, April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:470–2.
    1. Michaelis M, Doerr HW, Cinatl J., Jr An influenza A H1N1 virus revival - pandemic H1N1/09 virus. Infection. 2009;37:381–9. doi: 10.1007/s15010-009-9181-5.
    1. Yang ZF, Zhan YQ, Chen RC, Zhou R, Wang YT, Luo Y, et al. A prospective comparison of the epidemiological and clinical characteristics of pandemic (H1N1) 2009 influenza A virus and seasonal influenza A viruses in Guangzhou, South China in 2009. Jpn J Infect Dis. 2012;65:208–14. doi: 10.7883/yoken.65.208.
    1. De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006;5:1015–25. doi: 10.1038/nrd2175.
    1. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev. 2006;11
    1. Richman DD. Antiviral drug resistance. Antiviral Res. 2006;71:117–21. doi: 10.1016/j.antiviral.2006.03.004.
    1. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175–81. doi: 10.1016/S0140-6736(05)67338-2.
    1. Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother. 2010;54:1102–10. doi: 10.1128/AAC.01417-09.
    1. Centers for Disease Control and Prevention (CDC) Update: influenza activity - United States, August 30-October 31, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1236–41.
    1. Yang ZF, Guan WD, Xu GR, Li MY, Mo ZY, Luo Y, et al. Adamantane restslance among seasonal influenza A viruses between January to October in Guangzhou, 2009. Zhonghua Jie He He Hu Xi Za Zhi. 2011;34:95–9.
    1. Hama R, Jones M, Okushima H, Kitao M, Noda N, Hayashi K, et al. Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza. Int J Risk Saf Med. 2011;23:201–15.
    1. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284–92. doi: 10.1128/AAC.00555-08.
    1. Meijer A, Lackenby A, Hungnes O, Lina B. van-der-Werf S, Schweiger B, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season. Emerg Infect Dis. 2009;15:552–60. doi: 10.3201/eid1504.181280.
    1. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009;301:1034–41. doi: 10.1001/jama.2009.294.
    1. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 2009;83:90–3. doi: 10.1016/j.antiviral.2009.03.003.
    1. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med. 2009;360:953–6. doi: 10.1056/NEJMp0900648.
    1. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis. 2008;21:626–38. doi: 10.1097/QCO.0b013e3283199797.
    1. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998;178:1257–62. doi: 10.1086/314440.
    1. Krumholz HM, Jackevicius CA, Ross JS. Tamiflu: 14 flu seasons and still questions. BMJ. 2013;346:f547. doi: 10.1136/bmj.f547.
    1. Ganlin D The cfinic observation of 100 cases with acute pharyngitis cured by composite Banlangen tablet. J Precl1n Med Coll Siiandong Med Univ. 2002;16:93–4.
    1. Min TBNWDPLFCWZZZXFRHDaZ Efficacy of treatment of influenza A (H1N1) with oseltamivir phosphate and isatis root granules. Med J Chin PAPF. 2013;24:6.
    1. Yang ZF, Wang YT, Qin S, Zhao SS, Zhao YS, Lin Q, et al. The Effects of a Hot Water Soluble Extract (S-03) Isolated from Isatis Indigotica Root on Inf luenza A and B Viruses in vitro. Bing Du Xue Bao. 2011;27:218–23.
    1. Yang Z, Wang Y, Zhong S, Zhao S, Zeng X, Mo Z, et al. In vitro inhibition of influenza virus infection by a crude extract from Isatis indigotica root resulting in the prevention of viral attachment. Mol Med Rep. 2012;5:793–9.
    1. Yang Z, Wang Y, Zheng Z, Zhao S, Zhao J, Lin Q, et al. Antiviral activity of Isatis indigotica root-derived clemastanin B against human and avian influenza A and B viruses in vitro. Int J Mol Med. 2013;31:867–73.
    1. Mok CK, Kang SS, Chan RW, Yue PY, Mak NK, Poon LL, et al. Anti-inflammatory and antiviral effects of indirubin derivatives in influenza A (H5N1) virus infected primary human peripheral blood-derived macrophages and alveolar epithelial cells. Antiviral Res. 2014;106:95–104. doi: 10.1016/j.antiviral.2014.03.019.
    1. World Health Organization. Influenza (Seasonal). March 2014. .
    1. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group JAMA. 2000;283:1016–24.
    1. Duan ZP, Jia ZH, Zhang J, Liu S, Chen Y, Liang LC, et al. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J (Engl) 2011;124:2925–33.
    1. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group Lancet. 2000;355:1845–50.
    1. Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Gu L, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med. 2011;155:217–25. doi: 10.7326/0003-4819-155-4-201108160-00005.
    1. Shin EK, Kim DH, Lim H, Shin HK, Kim JK. The anti-inflammatory effects of a methanolic extract from Radix Isatidis in murine macrophages and mice. Inflammation. 2010;33:110–8. doi: 10.1007/s10753-009-9164-9.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir